DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

Molecular Imaging Homepage

Blue Earth Diagnostics inks Axumin deal with Seibersdorf Laboratories Manufacturing and distribution in certain European countries

Two new imaging agents may help physicians make better and quicker treatment decisions Could determine therapy response in 24 hours

Researchers develop targeted alpha therapy protocol for prostate cancer Determines most effective therapy with the least number of side effects

Eyeing theranostics, Sofie Biosciences completes acquisition of Zevacor Pharma Growth of FDG also influenced decision

Blue Earth Diagnostics partners with GE to manufacture Axumin PET agent in UK Agreements were made in other European countries

RefleXion Medical selects MedCrypt to secure its new radiotherapy technology Updated FDA guidelines put cybersecurity at forefront

PET imaging used for the first time to evaluate Zika virus in mouse model May aid in development of therapeutic agents

Philips introduces its CardioMD IV SPECT system at ASNC meeting Smaller footprint and lower cost of ownership

PET/MR scans can assess pediatric cancer survivor health Study targets chemotherapy after-effects in young patients

New publication calls for greater research and investment in theranostics Imaging a future with dedicated theranostics treatment centers

Prostate cancer found by PET/CT,
missed by conventional imaging

PET/CT with Ga-68 finds prostate cancer sooner than conventional imaging

by John W. Mitchell , Senior Correspondent
In what researchers are describing as the first prospective study of its kind in Australia, earlier detection for men with prostate cancer was realized using PET/CT scanning using Ga-68. The ensuing earlier detection changed treatment plans in 51 percent of cases – especially for patients with recurrent disease – to improve outcomes.

The study was presented at the 2017 SNMMI meeting in Denver.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



“Ga68 PSMA scanning is a game changer in the evaluation of patients with prostate cancer, and has been consistently shown to represent a substantial improvement over conventional imaging for the staging of prostate cancer,” Paul J. Roach, MBBS, head of the Department of Nuclear Medicine at Royal North Shore Hospital in Sydney, Australia, told HCB News.

According to Roach, the Ga68-PSMA PET/CT scan revealed disease that was not previously suspected by the referring clinician in the prostate bed (27 percent of patients), locoregional lymph nodes (39 percent of patients) and distant metastatic disease (16 percent of patients).

The study involved 431 patients over 18 months from four medical centers in Australia.

Nuclear Medicine specialists performed PET/CT in concert with an injected imaging agent composed of a tiny amount of a radioactive material called gallium-68 (Ga-68) and another molecular compound). Once administered, the agent zeros in on areas where the protein is being over-expressed on cell surfaces — including cancer that has spread from the prostate to other organs.

The radioactive markers distributed across these areas of PSMA over-expression emit a signal that is picked up by the PET scanner. A highly accurate map of the disease is then constructed to guide treatment.

“This is likely to become the primary imaging test for many patients with prostate cancer, and will replace conventional imaging in many cases,” said Roach. “Given the prevalence of prostate cancer, this will lead to a large increase in referrals to Nuclear Medicine/PET centers for Ga68 PSMA PET/CT scans worldwide.”

He added that he believes the study lends evidence to the position that the procedure should be covered by payors as a standard screening for prostate cancer.

According to the American Cancer Society, prostate cancer is the second most diagnosed cancer among American men. About 160,00 cases are estimated to be diagnosed this year, with an expected 27,000 deaths.

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED